Levi & Korsinsky, LLP: Clinical Trial Failures and Market Reaction at Issue In Mereo BioPharma Litigation

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- From a closing price of $2.31 on December 26, 2025, Mereo BioPharma Group plc (NASDAQ: MREO) shares plummeted to $0.29 on December 29, 2025—a decline of more than 87.7%—as corrective disclosures allegedly revealed that neither the ORBIT nor COSMIC Phase 3 studies achieved statistical significance. Investors have until April 6, 2026 to seek lead plaintiff status. See if you can recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-75 ...